For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

Keyword

E2108: Systemic therapy plus early local therapy versus systemic therapy alone i...

Dr Seema Ahsan Khan - Northwestern Memorial Hospital, Chicago, USA

E2108: Systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer ( Dr Seema Ahsan Khan - Northwestern Memorial Hospital, Chicago, USA )

KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy f...

Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York City, USA

KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy for extensive-stage small-cell lung cancer ( Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York City, USA )

EAU guidelines for treating patients with advanced prostate cancer

Dr Eleni Efstathiou, Prof Álvaro Pinto, Prof Nicolas Mottet and Prof Heather Pay...

EAU guidelines for treating patients with advanced prostate cancer ( Dr Eleni Efstathiou, Prof Álvaro Pinto, Prof Nicolas Mottet and Prof Heather Payne )

Cumulative incidence of financial hardship in metastatic colorectal cancer patie...

Dr Veena Shankaran - Fred Hutchinson Cancer Research Center, Seattle, USA

Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD ( Dr Veena Shankaran - Fred Hutchinson Cancer Research Center, Seattle, USA )

Denosumab in multiple myeloma patients with renal insufficiency

Dr Elizabeth O'Donnell - Massachusetts General Hospital, Boston, USA

Denosumab in multiple myeloma patients with renal insufficiency ( Dr Elizabeth O'Donnell - Massachusetts General Hospital, Boston, USA )

Association of BRCA alternations with response to PARP inhibitors in metastatic ...

Dr Emmanuel Antonarakis - John Hopkins Sidney Kimmel Comprehensive Cancer Center...

Association of BRCA alternations with response to PARP inhibitors in metastatic castration-resistant prostate cancer ( Dr Emmanuel Antonarakis - John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )

LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progres...

Prof Michael Hofman - Peter MacCallum Cancer Centre, Melbourne, Australia

LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progressing after docetaxel ( Prof Michael Hofman - Peter MacCallum Cancer Centre, Melbourne, Australia )

The paediatric precision oncology study INFORM: Clinical outcome and benefit for...

Dr Cornelis van Tilburg - Hopp Children's Cancer Center Heidelberg, Heidelberg, ...

The paediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups ( Dr Cornelis van Tilburg - Hopp Children's Cancer Center Heidelberg, Heidelberg, Germany )

Maintenance avelumab plus best supportive care (BSC) versus BSC alone after chem...

Prof Thomas Powles - Barts Cancer Institute, London, UK

Maintenance avelumab plus best supportive care (BSC) versus BSC alone after chemotherapy in advanced urothelial carcinoma ( Prof Thomas Powles - Barts Cancer Institute, London, UK )

Brigatinib for NSCLC, latest research and overcoming complications

Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA

Brigatinib for NSCLC, latest research and overcoming complications ( Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA )

Sym015 shows superior specificity compared to TKIs for NSCLC

Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA

Sym015 shows superior specificity compared to TKIs for NSCLC ( Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA )

CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell th...

Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA

CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy for r/r multiple myeloma ( Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA )

More from ecancer